Skip to main content

Adenoviruses are being explored as vectors for vaccines against various infectious diseases, such as COVID-19, and as vectors for gene therapy purposes against many heritable diseases. Pre-existing immune responses towards adenoviral vectors can limit the use of a vector. Therefore, a significant interest exists to vectorize novel adenoviral types that have low seroprevalence in the human population.

Our new publication, published in the peer-reviewed Journal of Virology, describes the discovery and vectorization of a chimeric human adenovirus, which we call HAdV-20-42-42. This study has been part of the AdVec consortium, with partners University of Edinburgh, Umeå University and Janssen Vaccines and Prevention.

Our data demonstrates that we have successfully vectorized a novel adenovirus type candidate with low seroprevalence. The cell transduction data and antigen-specific immune responses induced in vivo demonstrate that this vector is highly promising for the development of gene therapy and vaccine products.

This study was made possible by funding from FP7 Marie Curie Actions via the AdVec consortium (grant agreement number 324325). In addition, the project received funding from the European Union’s Horizon 2020 research and innovation program (grant agreement number 825670).

Licensing of the HAdV-20-42-42 vector

For the development of gene therapy products, Batavia now offers this adenoviral vector for licensing. Please contact us for more information on the vector, our R&D services, process development and manufacturing package.

SIDUS® Technology

Batavia has extensive experience in the development and manufacturing of viral vectors. Under our SIDUS brand we market our biological materials suitable for the production of vector-based products. Various cell lines and vector systems are available for viral vector-based vaccine, oncolytic and gene therapy products.

 

Link to full article